SYNDAX PHARMACEUTICALS INC (SNDX) Fundamental Analysis & Valuation

NASDAQ:SNDX • US87164F1057

Current stock price

24.41 USD
-0.35 (-1.41%)
Last:

This SNDX fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

1

1. SNDX Profitability Analysis

1.1 Basic Checks

  • In the past year SNDX has reported negative net income.
  • In the past year SNDX has reported a negative cash flow from operations.
  • In the past 5 years SNDX reported 4 times negative net income.
  • SNDX had negative operating cash flow in 4 of the past 5 years.
SNDX Yearly Net Income VS EBIT VS OCF VS FCFSNDX Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 -100M -200M -300M

1.2 Ratios

  • SNDX has a Return On Assets of -53.88%. This is comparable to the rest of the industry: SNDX outperforms 44.10% of its industry peers.
  • SNDX's Return On Equity of -441.62% is on the low side compared to the rest of the industry. SNDX is outperformed by 76.02% of its industry peers.
Industry RankSector Rank
ROA -53.88%
ROE -441.62%
ROIC N/A
ROA(3y)-44.01%
ROA(5y)-31.3%
ROE(3y)-196.68%
ROE(5y)-123.18%
ROIC(3y)N/A
ROIC(5y)N/A
SNDX Yearly ROA, ROE, ROICSNDX Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 -100 -200 -300 -400

1.3 Margins

  • SNDX has a better Gross Margin (95.96%) than 96.33% of its industry peers.
  • SNDX does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 95.96%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
SNDX Yearly Profit, Operating, Gross MarginsSNDX Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 -1K -2K -3K -4K -5K

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

3

2. SNDX Health Analysis

2.1 Basic Checks

  • SNDX does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • SNDX has more shares outstanding than it did 1 year ago.
  • The number of shares outstanding for SNDX has been increased compared to 5 years ago.
  • Compared to 1 year ago, SNDX has a worse debt to assets ratio.
SNDX Yearly Shares OutstandingSNDX Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 20M 40M 60M 80M
SNDX Yearly Total Debt VS Total AssetsSNDX Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 200M 400M 600M

2.2 Solvency

  • Based on the Altman-Z score of -1.61, we must say that SNDX is in the distress zone and has some risk of bankruptcy.
  • With a Altman-Z score value of -1.61, SNDX perfoms like the industry average, outperforming 51.06% of the companies in the same industry.
  • A Debt/Equity ratio of 5.32 is on the high side and indicates that SNDX has dependencies on debt financing.
  • SNDX's Debt to Equity ratio of 5.32 is on the low side compared to the rest of the industry. SNDX is outperformed by 81.24% of its industry peers.
Industry RankSector Rank
Debt/Equity 5.32
Debt/FCF N/A
Altman-Z -1.61
ROIC/WACCN/A
WACC8.98%
SNDX Yearly LT Debt VS Equity VS FCFSNDX Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 200M -200M 400M

2.3 Liquidity

  • SNDX has a Current Ratio of 4.40. This indicates that SNDX is financially healthy and has no problem in meeting its short term obligations.
  • With a Current ratio value of 4.40, SNDX perfoms like the industry average, outperforming 51.26% of the companies in the same industry.
  • SNDX has a Quick Ratio of 4.12. This indicates that SNDX is financially healthy and has no problem in meeting its short term obligations.
  • SNDX's Quick ratio of 4.12 is in line compared to the rest of the industry. SNDX outperforms 51.64% of its industry peers.
Industry RankSector Rank
Current Ratio 4.4
Quick Ratio 4.12
SNDX Yearly Current Assets VS Current LiabilitesSNDX Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 200M 400M 600M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

7

3. SNDX Growth Analysis

3.1 Past

  • The Earnings Per Share has grown by an nice 11.80% over the past year.
  • Looking at the last year, SNDX shows a very strong growth in Revenue. The Revenue has grown by 628.88%.
  • SNDX shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 158.26% yearly.
EPS 1Y (TTM)11.8%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%29.09%
Revenue 1Y (TTM)628.88%
Revenue growth 3YN/A
Revenue growth 5Y158.26%
Sales Q2Q%794.9%

3.2 Future

  • Based on estimates for the next years, SNDX will show a very strong growth in Earnings Per Share. The EPS will grow by 25.04% on average per year.
  • The Revenue is expected to grow by 45.49% on average over the next years. This is a very strong growth
EPS Next Y52.05%
EPS Next 2Y39.01%
EPS Next 3Y32.18%
EPS Next 5Y25.04%
Revenue Next Year109.31%
Revenue Next 2Y71.76%
Revenue Next 3Y59.76%
Revenue Next 5Y45.49%

3.3 Evolution

  • Although the future Revenue growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
SNDX Yearly Revenue VS EstimatesSNDX Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2024 2025 2026 2027 2028 2029 2030 2031 2032 2033 500M 1B 1.5B
SNDX Yearly EPS VS EstimatesSNDX Yearly EPS VS EstimatesYearly EPS VS Estimates 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 2033 0 2 -2 4 -4 6

More info and screens

Find the best growth stocksShow best growing peers

1

4. SNDX Valuation Analysis

4.1 Price/Earnings Ratio

  • The Price/Earnings Ratio is negative for SNDX. In the last year negative earnings were reported.
  • Also next year SNDX is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
SNDX Price Earnings VS Forward Price EarningsSNDX Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
SNDX Per share dataSNDX EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 -1 -2 -3

4.3 Compensation for Growth

  • A more expensive valuation may be justified as SNDX's earnings are expected to grow with 32.18% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y39.01%
EPS Next 3Y32.18%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. SNDX Dividend Analysis

5.1 Amount

  • SNDX does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

SNDX Fundamentals: All Metrics, Ratios and Statistics

SYNDAX PHARMACEUTICALS INC

NASDAQ:SNDX (4/10/2026, 10:58:07 AM)

24.41

-0.35 (-1.41%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)02-26
Earnings (Next)05-04
Inst Owners116.88%
Inst Owner Change0%
Ins Owners1.63%
Ins Owner Change10.19%
Market Cap2.15B
Revenue(TTM)172.60M
Net Income(TTM)-285.42M
Analysts87
Price Target40.99 (67.92%)
Short Float %23.73%
Short Ratio15.36
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-13.34%
Min EPS beat(2)-30.92%
Max EPS beat(2)4.24%
EPS beat(4)3
Avg EPS beat(4)5.26%
Min EPS beat(4)-30.92%
Max EPS beat(4)27.8%
EPS beat(8)6
Avg EPS beat(8)-38.36%
EPS beat(12)10
Avg EPS beat(12)-23.19%
EPS beat(16)14
Avg EPS beat(16)-15.89%
Revenue beat(2)1
Avg Revenue beat(2)-0.46%
Min Revenue beat(2)-6.26%
Max Revenue beat(2)5.34%
Revenue beat(4)3
Avg Revenue beat(4)18.48%
Min Revenue beat(4)-6.26%
Max Revenue beat(4)38.73%
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)2.02%
PT rev (3m)2.22%
EPS NQ rev (1m)-11.85%
EPS NQ rev (3m)-2%
EPS NY rev (1m)0%
EPS NY rev (3m)8.77%
Revenue NQ rev (1m)3.33%
Revenue NQ rev (3m)8.2%
Revenue NY rev (1m)-2.4%
Revenue NY rev (3m)-2.9%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 12.47
P/FCF N/A
P/OCF N/A
P/B 33.31
P/tB 33.31
EV/EBITDA N/A
EPS(TTM)-3.29
EYN/A
EPS(NY)-1.58
Fwd EYN/A
FCF(TTM)-3.66
FCFYN/A
OCF(TTM)-3.66
OCFYN/A
SpS1.96
BVpS0.73
TBVpS0.73
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -53.88%
ROE -441.62%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 95.96%
FCFM N/A
ROA(3y)-44.01%
ROA(5y)-31.3%
ROE(3y)-196.68%
ROE(5y)-123.18%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score1
Asset Turnover0.33
Health
Industry RankSector Rank
Debt/Equity 5.32
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 3116.67%
Cap/Sales 0.11%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 4.4
Quick Ratio 4.12
Altman-Z -1.61
F-Score1
WACC8.98%
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)11.8%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%29.09%
EPS Next Y52.05%
EPS Next 2Y39.01%
EPS Next 3Y32.18%
EPS Next 5Y25.04%
Revenue 1Y (TTM)628.88%
Revenue growth 3YN/A
Revenue growth 5Y158.26%
Sales Q2Q%794.9%
Revenue Next Year109.31%
Revenue Next 2Y71.76%
Revenue Next 3Y59.76%
Revenue Next 5Y45.49%
EBIT growth 1Y19.64%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year46.75%
EBIT Next 3Y35%
EBIT Next 5YN/A
FCF growth 1Y-17.56%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-17.49%
OCF growth 3YN/A
OCF growth 5YN/A

SYNDAX PHARMACEUTICALS INC / SNDX Fundamental Analysis FAQ

What is the fundamental rating for SNDX stock?

ChartMill assigns a fundamental rating of 3 / 10 to SNDX.


What is the valuation status for SNDX stock?

ChartMill assigns a valuation rating of 1 / 10 to SYNDAX PHARMACEUTICALS INC (SNDX). This can be considered as Overvalued.


What is the profitability of SNDX stock?

SYNDAX PHARMACEUTICALS INC (SNDX) has a profitability rating of 1 / 10.


Can you provide the expected EPS growth for SNDX stock?

The Earnings per Share (EPS) of SYNDAX PHARMACEUTICALS INC (SNDX) is expected to grow by 52.05% in the next year.